Clinical Trial Update: Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lenvatinib after progression on atezolizumab-bevacizumab for hepatocellular carcinoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• LENVIMA (lenvatinib)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Asan Medical Center | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING